CClinicalTrials.gg
CompletedNCT04937231Updated Oct 20, 2021

Comparative Effects of Aerobic Exercises, Resistance Training and Combined Training on Heart Failure Patients

An interventional study of Aerobic exercises and Resistance exercises in Heart Failure, sponsored by Riphah International University. Completed at 1 site in Pakistan. Open to participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-10-20.

Sponsored by Riphah International University · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Oct 2020, registered Jun 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
35 Years to 70 Years
Sex
All
01

Study summary

To compare the effectiveness of aerobic training and resistance training and combined training on heart failure patients.

02

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Aerobic Exercises
  • Resistance Training
  • Combined Training
03

In context

Heart Failure

5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.

This study's enrollment of 92 is above the median of 72 across 3,736 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,133 studies on the registry; 633 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Heart failure patients with ejection fraction greater than 35%

Exclusion criteria

Exclusion Criteria:

  • Patients with unstable angina
  • Patients who had severe pain in the lower limbs
  • Patients with Blood pressure greater than 190/120mmHg were excluded
  • Patients who had positive contraindication for cardiac rehabilitation were not admitted in this study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Aerobic exercises

    Treadmill and Cycle ergometer

    Other: Aerobic exercises

  • Experimental
    Resistance exercises

    unilateral leg press, Bilateral leg press, unilateral arm curls

    Other: Resistance exercises

  • Experimental
    Combined training

    Treadmill and Cycle ergometer along with resistive Training

    Other: Combined training

Interventions

  • OtherAerobic exercises

    For Week 1 and 2 : Treadmill 3-5days/weeks Intensity: 50-70 vo2 peak Or HRR 60-80% Duration of 10-20 minutes For Week 3 and 4; Cycle ergometer 3-5days/weeks Intensity: 50-70 vo2 peak Or HRR 60-80% Duration of 30-40 minutes

  • OtherResistance exercises

    For Week 1 and 2; 2 x 10 rep (unilateral leg press) 4x 12 reps (Bilateral leg press 1 x 8 rep ( unilateral arm curls For Week 3 and 4; 1 x 10 reps Shoulder press 1 x15 rep Bilateral knee extension 1 x 10 reps Bilateral arm curls

  • OtherCombined training

    For Week 1 and 2; Aerobic exercise on Treadmill along with dumbbell to perform upper limb exercises (biceps curls, side curls extensions, upright row, back fly) and used Thera band to perform lower limb exercises for 10-20 minutes For Week 3 and 4; Aerobic exercise on Treadmill along with dumbbell and Thera band to perform upper limb and lower limb exercises for 30-40 minutes

06

What researchers measure

Primary outcomes

  1. Hospital Anxiety and Depression Scale

    Hospital Anxiety and Depression Scale (HADS) is a 14-item scale with seven items each for anxiety and depression subscales. Scoring for each item ranges from zero to three. A subscale score \>8 denotes anxiety or depression. Changes from the Baseline will be measured.

    Time frame: 4th week

  2. Minnesota living with heart failure questionnaire

    Minnesota living with heart failure questionnaire (MLHFQ) is a self-administered, 21-item disease-specific instrument for patients with heart failure. MLHFQ is an instrument which has been widely used to assess quality of life among heart failure patients. Each item is scored in a 6-point Likert Scale (0 to 5), thus the total score could range from 0 to 105, with higher scores indicating more significant impairment in health-related quality of life. The MLHFQ has two domains; physical domain (eight items, score range from 0 to 40) and emotional domain (five items, score range from 0 to 25). Changes from the Baseline will be measured

    Time frame: 4th week

  3. 6 Min walk test (Distance in meters)

    Changes from the baseline, 6 Min Walk Distance (6 MWD) was used to measure Functional capacity. It is a sub maximal exercise test which can aid in assessing functional capacity of patients with cardiopulmonary diseases, in this test we find out the maximum distance in meters which an individual covers in 6 min without any support.

    Time frame: 4th Week

  4. Peak VO2 with formula

    A generalized equation can be used to determined Peak rate of oxygen consumption (peak VO2). The generalized equation can be used to accurately estimate mean peak VO2 from mean 6 MWD, among groups of patients with diverse diseases without the need for cardiopulmonary exercise testing. The equation is: Mean peak VO2(ml/kg/mins) = 4.948 + 0.023\*Mean 6 MWD (meter) Changes From the Baseline will be measured.

    Time frame: 4th Week

  5. Heart Rate/Pulse Rate

    Changes from baseline, Pulse rate was measured per minute through pulse oximeter. Crossly it was measure by Chest belt (Polar Heart Rate monitors). Changes from the Baseline will be measure.

    Time frame: 4th Week

07

Study locations

1 site
  • Rawalpindi Institute of Cardiology
    Rawalpindi, Punjab 44000, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04937231
Lead sponsor
Riphah International University
Responsible party
Sponsor
First posted
Jun 23, 2021
Start date
Oct 15, 2020
Primary completion
Sep 30, 2021
Completion
Sep 30, 2021
Last update
Oct 20, 2021

Study contacts

Muhammad Iqbal Tariq, MSCPPT
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion